Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared on X:
“Just out!! In NEJM – Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!
Implications are HUGE. This is a drug we spends billions on each year:
- Less side effects
- Less second cancers
- Similar overall survival
- Less cost
National NCI funded trial led by EGOG and joined by Alliance for Clinical Trials in Oncology and SWOG.”
Title: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Authors: Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar
Read The Full Article
Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, added:
“Congratulations to Vincent Rajkumar, Shaji Kumar and entire mmsm team for this massively important, relevant and timely study!
What an amazing overall team effort!”
Other articles about Multiple Myeloma on OncoDaily.